UCSF Neurologist Played Key Role in MS Research Turning to B-Cells, Essential Step to Ocrevus

                                                                  

Dr. Stephen Hauser, chair of the neurology department at the University of California San Francisco, was instrumental in the early research and later clinical trials that ultimately led to Ocrevus (ocrelizumab), the first therapy approved by the U.S. Food and Drug Administration (FDA) for both relapsing MS (RMS) and primary progressive multiple sclerosis (PPMS) patients.

Indeed, his work is testament to how scientific inquiry and determination might turn observations made in the lab into medicines for those in need.

Ocrevus is an antibody that targets CD20-positive B-cells, a type of cells from the immune system that are believed to contribute to myelin degeneration and neuronal damage, the hallmarks of MS. As such, and because of the efficacy and overall safety demonstrated in those clinical studies, Ocrevus holds considerable promise as an MS treatment — and one that might help at least some people with progressive disease.

MS Views and News is MAKING an IMPACT for those, affected by Multiple Sclerosis

Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews